IM HealthScience announced results of its "Functional Dyspepsia Adherence and Compliance Trial" for its FDgard product.
Researchers conducted an observational study of 600 patients who used FDgard to manage their functional dyspepsia.
Ann Arbor-based Michigan Medicine Gastroenterology Clinic Director William Chey, MD, presented the results at ACG 2017.
Here's what you should know:
1. Approximately 95 percent of patients experienced either major or moderate improvements of their functional dyspepsia.
2. Concerning epigastric pain syndrome, 92.5 percent of patients experienced improved upper abdominal pain.
3. Around 86.5 percent of postprandial distress syndrome patients achieved symptom relief within two hours of taking FDgard.
ACG 2017 took place in Orlando, Fla., Oct. 13 to Oct. 18.